Omega Healthcare Investors, Inc.
OHI Real Estate Reit Healthcare Facilities
Omega Healthcare Investors, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 13.2% from fiscal 2024.
- Revenue
- +9.30%
- EPS
- −52.4%
- Free cash flow
- −12.1%
- Total debt
- −19.5%
Quarter to September 2026, against a year earlier
Follow OHI
Alert me
Omega Healthcare Investors, Inc. (OHI) valuation and DCF model
At $48.21 the price implies FFO a share growing 3.2% a year for ten years.
FFO a share grew 1.4% a year over the last ten years, 4.3% over the last five. The price asks for about twice its ten-year rate. The industry’s median company is priced for 5.1%.
In December 2017 the price assumed −5.2% a year; Omega Healthcare Investors, Inc. went on to grow FFO a share −0.8% a year to FY2025.
Q3 2026’s FFO a share is the $0.60 Omega Healthcare Investors, Inc. reported, in its results release. Ours, from its filings, came out 8.1% lower. It reported AFFO of $0.82 a share for Q3 2026.
- The price needs
- 3.2% a year for ten years
- $48.21
- today’s price
- Its base case
- 1.4% a year for five years, then 0.9%
- $41.34
- 14.2% below today’s price
Base case on its own ten-year record Omega Healthcare Investors, Inc.’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$19.75 10 years of FFO+$21.59 terminal value=$41.34 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 19.16× | 22.54× | 28.70× | 33% below | 25.44× | 25% below | |
| P/FCF | 43.45× | 58.37× | 48.88× | 11% below | 18.55× | 134% above | |
| P/B | 2.54× | 2.14× | 1.98× | 28% above | 1.72× | 48% above | |
| EV/EBITDA | 17.58× | 15.89× | 16.11× | 9% above | 17.56× | 0% above | |
| EV/Sales | 14.07× | 12.87× | 13.00× | 8% above | 8.15× | 73% above | |
| P/FFO | 16.68× | 15.07× | 13.83× | 21% above | — | — |
OHI trades at 14.07× EV/Sales, against a 10-year average of 13.00× (range 10.90×–15.22×). That is dearer than 78% of the last 9 year-end readings; re-rating to the average implies $43.61 per share.